Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* H. pylori eradication (in combination with antibiotics)
### Adult Dosing
* **GERD:** 20 mg once daily for up to 8 weeks.
* **Erosive Esophagitis:** 40 mg once daily for up to 8 weeks. May be continued for up to 16 weeks if needed for healing.
* **Maintenance of Healing Erosive Esophagitis:** 20 mg once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg twice daily, may be increased as needed. Doses up to 240 mg daily have been used.
* **H. pylori Eradication:** 40 mg twice daily for 7-14 days in combination with amoxicillin and clarithromycin or other approved regimens.
### Pediatric Dosing
* **GERD and Erosive Esophagitis (12 years and older):** 40 mg once daily for up to 8 weeks.
Dosing for pediatric patients younger than 12 years is not established by the FDA. Local protocols or specialist guidance may apply.
### Dose Adjustments
No dose adjustment is generally needed for renal or hepatic impairment, though caution is advised in severe hepatic impairment.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* Long-term use: Increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, hypomagnesemia.
### Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, certain HIV protease inhibitors (e.g., atazanavir, nelfinavir).
* **Warfarin:** May increase INR and PT. Monitor closely.
* **Methotrexate:** May increase methotrexate levels. Consider interruption of pantoprazole.
### Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, tetany, seizures).
* Consider monitoring vitamin B12 levels with prolonged therapy.
* Monitor bone mineral density in patients at risk for osteoporosis.
### Clinical Pearls
* Administer 30-60 minutes before a meal.
* Swallow delayed-release capsules or tablets whole; do not chew or crush.
* Pantoprazole suspension can be administered via oral or nasogastric tube.
* Long-term PPI use should be reserved for specific indications with periodic re-evaluation.
***
*Please verify this information with the most current prescribing information, as drug information can change.*
